Skyepharma Advances Oncology Contract Manufacturing with French Facility Launch

• Skyepharma’s MMPP area is now fully operational, with a projected €10 million annual revenue from oncology-related CDMO services.

• The facility has signed four industrial partnerships and created 15 specialised jobs in R&D, production, and quality.

Skyepharma has marked six months of activity at its MMPP (Medicines to be Handled with Particular Care) facility, dedicated to the development and production of high-potency oral oncology drugs. The French CDMO has shared early achievements from the site, located in France, which is equipped to handle cytotoxic and cytostatic compounds to OEB4/5+ standards.

Since the launch of the 450 m² GMP-compliant unit, Skyepharma has secured four industrial partnerships in the oncology space, created 15 specialised roles, and expects oncology-related operations to generate €10 million in annual revenue. The facility offers a manufacturing capacity of more than 80 million tablets and 200 million capsules per year.

The site plays a strategic role in reshoring the production of essential medicines. “Today, we are fully equipped to contribute to the development of innovative treatments for oncological diseases. Moreover, by reshoring strategic medicines to French territory, we aim to play a key role in mitigating the risks of shortages,” said David Lescuyer, President of Skyepharma.

Skyepharma’s MMPP unit is one of the few CDMOs in France capable of managing HPAPIs for oral anticancer treatments. The site integrates formulation, analytics, packaging, and regulatory services, and is tailored for small-batch, high-value contract manufacturing aimed at biotech and specialty pharma clients.

Partially funded through the France Relance programme, the facility underpins national and European ambitions for healthcare resilience. It also complements Skyepharma’s broader capabilities, including proprietary drug delivery platforms and Skyehub®, a programme supporting the industrialisation of complex biomedicines.